Wave Life Sciences Ltd. (NASDAQ:WVE) stands out as one of the best small-cap biotech stocks to buy, with significant potential. Jefferies maintains a “Buy” rating, citing the company’s improving competitive positioning. Despite missing revenue forecasts in Q3, Wave Life Sciences reduced its net loss and extended its cash runway through Q2 2027. The company remains focused on advancing its RNA-based therapies.

Read more at Yahoo Finance: Jefferies Maintains “Buy” Rating on Wave Life Sciences (WVE) Amid Its Improving Competitive Positioning